secukinumab

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2018
0204020122018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
BACKGROUND Secukinumab is an anti-interleukin-17A monoclonal antibody that has been shown to control the symptoms of ankylosing… (More)
  • table 3
  • table 4
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND In a phase 2 study, the inhibition of the interleukin-17A receptor improved signs and symptoms of psoriatic arthritis… (More)
  • table 1
  • table 2
  • figure 1
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Interleukin 17A is a proinflammatory cytokine that is implicated in the pathogenesis of psoriatic arthritis. We… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2015
2015
BACKGROUND Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, demonstrated efficacy and safety in moderate-to… (More)
Is this relevant?
2015
2015
BACKGROUND Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has shown superior efficacy to etanercept with… (More)
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluated secukinumab, a fully human… (More)
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND Ankylosing spondylitis is a chronic immune-mediated inflammatory disease characterised by spinal inflammation… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2013
Highly Cited
2013
OBJECTIVE To assess the safety and efficacy of secukinumab, a fully human monoclonal anti-interleukin-17A antibody, in patients… (More)
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND Conventional systemic therapies for plaque psoriasis have not fully met the needs of patients, and although current… (More)
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND Interleukin (IL)-17A has major proinflammatory activity in psoriatic lesional skin. OBJECTIVES To assess the… (More)
Is this relevant?